{
    "id": "ffed04b0-500b-460e-be18-8d304f8f8d7b",
    "indications": {
        "text": "adalimumab-ryvk tumor necrosis factor ( tnf ) blocker indicated : rheumatoid arthritis ( rheumatoid arthritis ) : reducing signs symptoms , inducing major response , inhibiting progression structural damage , improving physical function adult patients moderately severely active rheumatoid arthritis . ( 1.1 ) juvenile idiopathic arthritis ( jia ) : reducing signs symptoms moderately severely active polyarticular jia patients 2 years age older . ( 1.2 ) psoriatic arthritis ( psa ) : reducing signs symptoms , inhibiting progression structural damage , improving physical function adult patients active psa . ( 1.3 ) ankylosing spondylitis ( ) : reducing signs symptoms adult patients active . ( 1.4 ) crohn \u2019 disease ( cd ) : treatment moderately severely active crohn \u2019 disease adults pediatric patients 6 years age older . ( 1.5 ) ulcerative colitis ( uc ) : treatment moderately severely active ulcerative colitis adult patients . ( 1.6 ) limitations : effectiveness established patients lost response intolerant tnf blockers . plaque psoriasis ( ps ) : treatment adult patients moderate severe chronic plaque psoriasis candidates systemic therapy phototherapy , systemic therapies medically less appropriate . ( 1.7 ) hidradenitis suppurativa ( hs ) : treatment moderate severe hidradenitis suppurativa adult patients ( 1.8 ) uveitis ( uv ) : treatment non-infectious intermediate , posterior , panuveitis adult patients ( 1.9 )",
        "doid_entities": [
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "juvenile idiopathic arthritis (DOID:676)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_676"
            },
            {
                "text": "psoriatic arthritis (DOID:9008)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9008"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "ulcerative colitis (DOID:8577)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8577"
            },
            {
                "text": "colitis (DOID:0060180)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060180"
            },
            {
                "text": "psoriasis (DOID:8893)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8893"
            },
            {
                "text": "hidradenitis (DOID:2282)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2282"
            },
            {
                "text": "hidradenitis suppurativa (DOID:2280)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2280"
            },
            {
                "text": "uveitis (DOID:13141)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13141"
            },
            {
                "text": "panuveitis (DOID:12030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12030"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hidradenitis suppurativa",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_387"
            }
        ]
    },
    "contraindications": {
        "text": "administer subcutaneous injection . ( 2 ) rheumatoid arthritis , psoriatic arthritis , ankylosing spondylitis ( 2.1 ) : adults : 40 mg every week . patients rheumatoid arthritis receiving methotrexate may benefit increasing 40 mg every week 80 mg every week . juvenile idiopathic arthritis ( 2.2 ) : pediatric weight 2 years age older recommended 15 kg ( 33 lbs ) less 30 kg ( 66 lbs ) 20 mg every week 30 kg ( 66 lbs ) greater 40 mg every week crohn 's disease ( 2.3 ) : adults : 160 mg day 1 ( given one day split two consecutive days ) , 80 mg day 15 , 40 mg every week starting day 29. pediatric patients 6 years age older : pediatric weight recommended days 1 15 starting day 29 17 kg ( 37 lbs ) less 40 kg ( 88 lbs ) day 1 : 80 mg day 15 : 40 mg 20 mg every week 40 kg ( 88 lbs ) greater day 1 : 160 mg ( single dose split two consecutive days ) day 15 : 80 mg 40 mg every week ulcerative colitis ( 2.4 ) : adults : 160 mg day 1 ( given one day split two consecutive days ) , 80 mg day 15 , 40 mg every week starting day 29. discontinue patients without evidence remission eight weeks ( day 57 ) . plaque psoriasis adult uveitis ( 2.5 ) : adults : 80 mg initial dose , followed 40 mg every week starting one week initial dose . hidradenitis suppurativa ( 2.6 ) : adults : day 1 : 160 mg ( given one day split two consecutive days ) day 15 : 80 mg day 29 subsequent doses : 40 mg every week 80 mg every week",
        "doid_entities": [
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "psoriatic arthritis (DOID:9008)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9008"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            },
            {
                "text": "juvenile idiopathic arthritis (DOID:676)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_676"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "ulcerative colitis (DOID:8577)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8577"
            },
            {
                "text": "colitis (DOID:0060180)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060180"
            },
            {
                "text": "psoriasis (DOID:8893)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8893"
            },
            {
                "text": "uveitis (DOID:13141)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13141"
            },
            {
                "text": "hidradenitis (DOID:2282)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2282"
            },
            {
                "text": "hidradenitis suppurativa (DOID:2280)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2280"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "adalimumab-ryvk injectionis supplied preservative-free , sterile , clear colorless solution subcutaneous . following packaging configurations available . adalimumab-ryvk autoinjector carton - 80 mg/0.8 ml ( one count ) adalimumab-ryvk supplied carton containing one alcohol prep one dose tray . dose tray consists single-dose autoinjector , containing 1 ml prefilled glass syringe fixed 29-gauge ( 1/2 inch ) needle , providing 80 mg/0.8 ml adalimumab-ryvk . adalimumab-ryvk autoinjector made natural rubber latex . ndc number ndc 51759-361-17. adalimumab-ryvk autoinjector carton - 80 mg/0.8 ml ( three count ) adalimumab-ryvk supplied carton containing foue alcohol preps three dose trays . dose tray consists single-dose autoinjector , containing 1 ml prefilled glass syringe fixed 29-gauge ( 1/2 inch ) needle , providing 80 mg/0.8 ml adalimumab-ryvk . adalimumab-ryvk autoinjector made natural rubber latex . ndc number ndc 51759-361-03. adalimumab-ryvk autoinjector carton - 40 mg/0.4 ml ( one count ) adalimumab-ryvk supplied carton containing one alcohol prep one dose tray . dose tray consists single-dose autoinjector , containing 1 ml prefilled glass syringe fixed 29-gauge ( 1/2 inch ) needle , providing 40 mg/0.4 ml adalimumab-ryvk . adalimumab-ryvk autoinjector made natural rubber latex . ndc number ndc 51759-360-17. adalimumab-ryvk autoinjector carton - 40 mg/0.4 ml ( two count ) adalimumab-ryvk supplied carton containing two alcohol preps two dose trays . dose tray consists single-dose autoinjector , containing 1 ml prefilled glass syringe fixed 29-gauge ( 1/2 inch ) needle , providing 40 mg/0.4 ml adalimumab-ryvk . adalimumab-ryvk autoinjector made natural rubber latex . ndc number ndc 51759-360-02. adalimumab-ryvk prefilled syringe carton - 80 mg/0.8 ml ( one count ) adalimumab-ryvk supplied carton containing two alcohol preps one dose tray . dose tray consists single-dose , 1 ml prefilled glass syringe fixed thin wall , 1/2 inch needle fitted plunger rod , finger grip rigid needle cover , providing 80 mg/0.8 ml adalimumab-ryvk . gray needle cover made natural rubber latex . ndc number ndc 51759-364-21. adalimumab-ryvk prefilled syringe carton - 40 mg/0.4 ml ( two count ) adalimumab-ryvk supplied carton containing two alcohol preps two dose trays . dose tray consists single-dose , 1 ml prefilled glass syringe fixed thin wall , 1/2 inch needle fitted plunger rod , finger grip rigid needle cover , providing 40 mg/0.4 ml adalimumab-ryvk . gray needle cover made natural rubber latex . ndc number ndc 51759-363-22. adalimumab-ryvk prefilled syringe carton - 20 mg/0.2 ml ( two count ) adalimumab-ryvk supplied carton containing two alcohol preps two dose trays . dose tray consists single-dose , 1 ml prefilled glass syringe fixed thin wall , 1/2 inch needle fitted plunger rod , finger grip rigid needle cover , providing 20 mg/0.2 ml adalimumab-ryvk . gray needle cover made natural rubber latex . ndc number ndc 51759-362-22. storage stability beyond expiration date container . adalimumab-ryvk must refrigerated 36\u00b0f 46\u00b0f ( 2\u00b0c 8\u00b0c ) . freeze . frozen even thawed . store original carton time protect light . needed , example traveling , adalimumab-ryvk may stored room temperature maximum 77\u00b0f ( 25\u00b0c ) period 30 days , protection light . adalimumab-ryvk discarded used within 30-day period . record date adalimumab-ryvk first removed refrigerator spaces provided carton dose tray . store adalimumab-ryvk extreme heat cold .",
    "adverseReactions": "none .",
    "ingredients": [],
    "organization": "Teva Pharmaceuticals USA, Inc.",
    "name": "Adalimumab-ryvk",
    "effectiveTime": "20241015",
    "indications_original": "Adalimumab-ryvk is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. ( 1.1 ) Juvenile Idiopathic Arthritis (JIA): Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. ( 1.2 ) Psoriatic Arthritis (PsA): Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. ( 1.3 ) Ankylosing Spondylitis (AS): Reducing signs and symptoms in adult patients with active AS. ( 1.4 ) Crohn\u2019s Disease (CD): Treatment of moderately to severely active Crohn\u2019s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Ulcerative Colitis (UC): Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Plaque Psoriasis (Ps): Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Hidradenitis Suppurativa (HS): treatment of moderate to severe hidradenitis suppurativa in adult patients ( 1.8 ) Uveitis (UV): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients ( 1.9 )",
    "contraindications_original": "Administer by subcutaneous injection. ( 2 ) Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis ( 2.1 ): Adults: 40 mg every other week. Some patients with RA not receiving methotrexate may benefit from increasing the dosage to 40 mg every week or 80 mg every other week. Juvenile Idiopathic Arthritis ( 2.2 ): Pediatric Weight 2 Years of Age and older Recommended Dosage 15 kg (33 lbs) to less than 30 kg (66 lbs) 20 mg every other week 30 kg (66 lbs) and greater 40 mg every other week Crohn's Disease ( 2.3 ): Adults: 160 mg on Day 1 (given in one day or split over two consecutive days), 80 mg on Day 15, and 40 mg every other week starting on Day 29. Pediatric Patients 6 Years of Age and Older: Pediatric Weight Recommended Dosage Days 1 and 15 Starting on Day 29 17 kg (37 lbs) to less than 40 kg (88 lbs) Day 1: 80 mg Day 15: 40 mg 20 mg every other week 40 kg (88 lbs) and greater Day 1: 160 mg (single dose or split over two consecutive days) Day 15: 80 mg 40 mg every other week Ulcerative Colitis ( 2.4 ): Adults: 160 mg on Day 1 (given in one day or split over two consecutive days), 80 mg on Day 15, and 40 mg every other week starting on Day 29. Discontinue in patients without evidence of clinical remission by eight weeks (Day 57). Plaque Psoriasis or Adult Uveitis ( 2.5 ): Adults: 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose. Hidradenitis Suppurativa ( 2.6 ): Adults : Day 1: 160 mg (given in one day or split over two consecutive days) Day 15: 80 mg Day 29 and subsequent doses: 40 mg every week or 80 mg every other week",
    "warningsAndPrecautions_original": "Adalimumab-ryvk injectionis supplied as a preservative-free, sterile, clear and colorless solution for subcutaneous administration. The following packaging configurations are available.\n                  \n                     \n                        Adalimumab-ryvk Autoinjector Carton - 80 mg/0.8 mL (One Count)\n                        Adalimumab-ryvk is supplied in a carton containing one alcohol prep and one dose tray. The dose tray consists of a single-dose autoinjector, containing a 1 mL prefilled glass syringe with a fixed 29-gauge (1/2 inch) needle, providing 80 mg/0.8 mL of Adalimumab-ryvk. The Adalimumab-ryvk autoinjector is not made with natural rubber latex. The NDC number is NDC\u00a051759-361-17.\n                     \n                     \n                        Adalimumab-ryvk Autoinjector Carton - 80 mg/0.8 mL (Three Count)\n                        Adalimumab-ryvk is supplied in a carton containing foue alcohol preps and three dose trays. Each dose tray consists of a single-dose autoinjector, containing a 1 mL prefilled glass syringe with a fixed 29-gauge (1/2 inch) needle, providing 80 mg/0.8 mL of Adalimumab-ryvk. The Adalimumab-ryvk autoinjector is not made with natural rubber latex. The NDC number is NDC\u00a051759-361-03.\n                     \n                     \n                        Adalimumab-ryvk Autoinjector Carton - 40 mg/0.4 mL (One Count)\n                        Adalimumab-ryvk is supplied in a carton containing one alcohol prep and one dose tray. The dose tray consists of a single-dose autoinjector, containing a 1 mL prefilled glass syringe with a fixed 29-gauge (1/2 inch) needle, providing 40 mg/0.4 mL of Adalimumab-ryvk. The Adalimumab-ryvk autoinjector is not made with natural rubber latex. The NDC number is NDC\u00a051759-360-17.\n                     \n                     \n                        Adalimumab-ryvk Autoinjector Carton - 40 \n                        mg/0.4\n                         mL (Two Count)\n                        Adalimumab-ryvk is supplied in a carton containing two alcohol preps and two dose trays. Each dose tray consists of a single-dose autoinjector, containing a 1 mL prefilled glass syringe with a fixed 29-gauge (1/2 inch) needle, providing 40 mg/0.4 mL of Adalimumab-ryvk. The Adalimumab-ryvk autoinjector is not made with natural rubber latex. The NDC number is NDC\u00a051759-360-02.\n                        \n                           \u00a0\n                        \n                     \n                     \n                        Adalimumab-ryvk Prefilled Syringe Carton - 80 mg/0.8 mL (One Count)\n                        Adalimumab-ryvk is supplied in a carton containing two alcohol preps and one dose tray. The dose tray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, 1/2\u00a0inch needle and fitted with a plunger rod, finger grip and a rigid needle cover, providing 80 mg/0.8 mL of Adalimumab-ryvk. The gray needle cover is not made with natural rubber latex. The NDC number is NDC\u00a051759-364-21. \n                     \n                     \n                        Adalimumab-ryvk Prefilled Syringe Carton - 40 mg/0.4 mL (Two Count)\n                        Adalimumab-ryvk is supplied in a carton containing two alcohol preps and two dose trays. Each dose tray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, 1/2\u00a0inch needle and fitted with a plunger rod, finger grip and a rigid needle cover, providing 40 mg/0.4 mL of Adalimumab-ryvk. The gray needle cover is not made with natural rubber latex. The NDC number is NDC\u00a051759-363-22. \n                     \n                     \n                        Adalimumab-ryvk Prefilled Syringe Carton - 20 mg/0.2 mL (Two Count)\n                        Adalimumab-ryvk is supplied in a carton containing two alcohol preps and two dose trays. Each dose tray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, 1/2 inch needle and fitted with a plunger rod, finger grip and a rigid needle cover, providing 20 mg/0.2 mL of Adalimumab-ryvk. The gray needle cover is not made with natural rubber latex. The NDC number is NDC\u00a051759-362-22.\n                     \n                  \n                  \n                     Storage and Stability\n                  \n                  Do not use beyond the expiration date on the container. Adalimumab-ryvk must be refrigerated at 36\u00b0F to 46\u00b0F \n(2\u00b0C to 8\u00b0C). DO NOT FREEZE. Do not use if frozen even if it has been thawed.\n                  Store in original carton until time of administration to protect from light.\n                  If needed, for example when traveling, Adalimumab-ryvk may be stored at room temperature up to a maximum of 77\u00b0F (25\u00b0C) for a period of up to 30 days, with protection from light. Adalimumab-ryvk should be discarded if not used within the 30-day period. Record the date when Adalimumab-ryvk is first removed from the refrigerator in the spaces provided on the carton and dose tray. \n                  Do not store Adalimumab-ryvk in extreme heat or cold.",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Adalimumab-ryvk",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00051"
        }
    ]
}